Effects of COVID-19 Pandemic and Lockdown on Monitoring and Treatment Balance of Finnish Coronary Heart Disease and Type 2 Diabetes Patients.
HbA1c
LDL
electronic health records
interrupted time-series
Journal
Clinical epidemiology
ISSN: 1179-1349
Titre abrégé: Clin Epidemiol
Pays: New Zealand
ID NLM: 101531700
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
09
2022
accepted:
27
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
We aimed to examine the effect of the COVID-19 pandemic and lockdown on monitoring and treatment balance of Finnish coronary heart disease (CHD) and type 2 diabetes (T2D) patients. We used data from the electronic health records on 1604 CHD and 10,136 T2D patients aged 18‒85 years in Eastern Finland. Measurement and levels of low-density lipoprotein cholesterol (LDL) of CHD patients and glycated haemoglobin (HbA1c) of T2D patients were assessed monthly during January 2019-June 2021. Interrupted time-series analysis design was utilized to examine the effect of the lockdown on proportion of patients monitored and treatment balance. Reductions in frequencies of LDL testing of CHD and HbA1c testing of T2D patients were observed during the national lockdown. Downward trend in average LDL was observed from January 2019 until June 2021. Average HbA1c values increased from January 2019 to March 2020 with an additional increase by 2.04 mmol/mol (0.80 to 3.29) in April 2020. However, there was a downward trend in monthly average HbA1c during the lockdown until June 2021 with an additional change in level by 0.61 mmol/mol (95% CI 0.06 to 1.16) in July 2020. The lockdown decreased the frequency of monitoring among both CHD and T2D patients. Meanwhile, monthly average LDL had a steadily improving pattern in CHD patients during the follow-up while temporary worsening in HbA1c in patients with T2D was observed at the time of the lockdown. The lockdown may have introduced selection in patients who had their treatment outcomes monitored. Better self-management of risk factors among patients is also possible.
Identifiants
pubmed: 36387927
doi: 10.2147/CLEP.S387461
pii: 387461
pmc: PMC9664920
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1363-1373Informations de copyright
© 2022 Lavikainen et al.
Déclaration de conflit d'intérêts
JM is a founding partner of ESiOR Oy and a board member of Siltana Oy. These companies were not involved in carrying out this research. PL, M-LL, TR, LI, and TL declare no conflicts of interest.
Références
Ann Intern Med. 2004 Sep 21;141(6):421-31
pubmed: 15381515
Atherosclerosis. 2020 Mar;296:4-10
pubmed: 31999985
Foods. 2020 May 25;9(5):
pubmed: 32466106
Eur Heart J Qual Care Clin Outcomes. 2022 Jan 5;8(1):50-60
pubmed: 33017008
J Clin Pharm Ther. 2002 Aug;27(4):299-309
pubmed: 12174032
BMC Health Serv Res. 2022 Jun 1;22(1):725
pubmed: 35650580
Diabetol Metab Syndr. 2021 Sep 7;13(1):95
pubmed: 34493317
BMJ Qual Saf. 2022 Jul;31(7):503-514
pubmed: 34642228
Health Policy Technol. 2020 Dec;9(4):649-662
pubmed: 32874860
Diabetes Metab J. 2021 Jan;45(1):109-114
pubmed: 33264833
Obes Sci Pract. 2020 Aug 12;6(6):735-740
pubmed: 33354349
Nutrients. 2020 Jul 07;12(7):
pubmed: 32645970
Lancet Diabetes Endocrinol. 2021 Jul;9(7):413-415
pubmed: 33989537
BMC Fam Pract. 2020 Oct 10;21(1):208
pubmed: 33038926
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
Int J Environ Res Public Health. 2022 Jan 19;19(3):
pubmed: 35162117
Int J Public Health. 2018 May;63(4):547-551
pubmed: 29549396
Acad Pediatr. 2013 Nov-Dec;13(6 Suppl):S38-44
pubmed: 24268083
Nutrients. 2022 Mar 15;14(6):
pubmed: 35334894
Diabet Med. 2020 Jul;37(7):1146-1154
pubmed: 32392380
BMJ. 2000 Aug 12;321(7258):405-12
pubmed: 10938048
Appetite. 2021 Jan 1;156:104853
pubmed: 33038479